2014, Number 110
<< Back Next >>
Rev Enfer Infec Pediatr 2014; 27.28 (110)
Long QT Syndrome. Perspective on Prevention Medication Management in Infectious Diseases
Vázquez TÓ, Ignorosa AKR, Campos RT, Mier MM
Language: Spanish
References: 7
Page: 529-531
PDF size: 128.32 Kb.
Text Extraction
No abstract
REFERENCES
• Celaya LMC, Martínez BJ. Medicamentos y Prolongación de QT. Boletín Farmacológico de Navarra. 2013; 21: 1-7
• Gowda RM, Khan IA, Wilbur SL, Vasavada BC, Sacchi TJ. Torsade de pointes: The clinical considerations. Int J Cardiol 2004;96:1-6.
• Medeiros-Domingo A, Iturralde-Torres P, Canizales-Quinteros S, Hernández-Cruz A, Ma. Tusié-Luna MT. Nuevas perspectivas en el síndrome de QT largo. Rev Invest Clin 2007;59: 57-72.
• Kannankeril P, Roden DM, Dardar D. Drug-induced long QT Syndrome. Pharmacol Rev 2010;62:760-81
• Hötch C, Opezzo JAW, Taira CA. Intervalo QT prolongado inducido por fármacos desde el punto de vista de un farmacólogo. Rev Arg Cardiol. 2004; 72: 474-80.
• Owens RC, Nalin TD. Antimicrobial-Associated QT Interval Prolongation: Pointes of Interest. -Clin Infect Dis. 2006;43:1603- 11.
• Mahida S, Hogarth AJ, Cowan C, Tayebjee MH, Graham LN, Pepper CB. Genetics of congenital and druq-induced long QT syndromes: Current evidence and future research perspectives. I Interv Card Electrophysiol. 2013;37:9-19.
Full text